Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Nippon Soda discloses newest agents for lipid disorders

April 13, 2000

Chimeric GRF analogues with enhanced potency designed by Theratechnologies

April 13, 2000

New benzodiazepinone derivatives under study at Aventis as inhibitors of bone resorption

April 12, 2000

Proof of concept demonstrated for PPL's transgenic BSSL

April 12, 2000

Novel antidiabetics from Novo Nordisk act as normoglycemic agents

April 11, 2000

New formulation of Hectorol approved by FDA

April 11, 2000

Sonus signs agreement with SUNY to develop oxygen delivery systems

April 11, 2000

New program for bone disease therapy initiated by Aastrom Biosciences

April 11, 2000

Novel serotonergic compounds from Cerebrus particularly useful for obesity Rx

April 10, 2000

Obesity drug slated to enter phase I trials next month

April 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...